Proteomic Analyses in COVID-19-Associated Secondary Hemophagocytic Lymphohistiocytosis

Susan P Canny1,2, Ian B Stanaway3, Sarah E Holton4,5

  • 1Center for Fundamental Immunology, Benaroya Research Institute, Seattle, WA.

PubMed

Insights

COVID-19 patients can develop secondary hemophagocytic lymphohistiocytosis (sHLH). Specific proteins like soluble PD-L1 and immune pathway alterations are linked to severe COVID-19 and fatal outcomes in sHLH.

Area of Science:

  • Immunology
  • Virology
  • Genetics

Background:

  • COVID-19 can trigger a cytokine storm, resembling secondary hemophagocytic lymphohistiocytosis (sHLH).
  • Understanding the molecular mechanisms of COVID-19-associated sHLH is crucial for patient outcomes.

Purpose of the Study:

  • To investigate proteins associated with sHLH in COVID-19 patients.
  • To identify immune-related pathway defects in fatal COVID-19 cases with sHLH.

Main Methods:

  • Observational study of adult COVID-19 patients (n=264) with and without sHLH.
  • Plasma proteomics (O-link, SomaScan) and genomic sequencing of deceased patients.

Main Results:

  • 24 patients (9%) met sHLH criteria.
  • Elevated levels of soluble PD-L1, tumor necrosis factor-R1, and IL-18BP identified in COVID-19-associated sHLH.
  • Pathogenic variants in DOCK8 and TMPRSS15 found in fatal cases.

Conclusions:

  • Increased sPD-L1 and syntaxin pathway involvement suggest a key immune response role in COVID-19-associated sHLH.
  • Immune-related genetic alterations may contribute to hyperinflammation and mortality in severe COVID-19.
Abstract